The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans
Open accessAbstract
Cryptococcus neoformans isolates that exhibited unusual patterns of resistance to fluconazole and voriconazole were isolated from seven isolates from two different geographical regions: one isolate from an Israeli non-AIDS patient and six serial isolates from an Italian AIDS patient who had suffered six recurrent episodes of cryptococcal meningitis. Each isolate produced cultures with heterogeneous compositions in which most of the cells were susceptible, but cells highly resistant to fluconazole (MICs, ≥64 μg/ml) were recovered at a variable frequency (7 × 10 −3 to 4.6 × 10 −2 ). Evidence showed that this type of resistance is innate and is unrelated to drug exposure since the Israeli patient had never been treated with azoles or any other antimycotic agents. Analysis of clonal subpopulations of these two strains showed that they exhibited heterogeneous patterns of resistance. The number of subpopulations which grew on fluconazole or voriconazole agar declined progressively with increasing azole concentration without a sharp cutoff point. For the Italian serial isolates, the number of clonal populations resistant to fluconazole (64 μg/ml) and voriconazole (1 μg/ml) increased steadily, yielding the highest number for the isolate from the last episode. Attempts to purify a sensitive subpopulation failed, but clones highly resistant to fluconazole (100 μg/ml) and moderately resistant to voriconazole (1 μg/ml) always produced a homogeneous population of resistant cells. Upon maintenance on drug-free medium, however, the majority of the homogeneously resistant cells of these subclones lost their resistance and returned to the stable initial heteroresistant phenotype. The pattern of heteroresistance was not affected by the pH or osmolarity of the medium but was influenced by temperature. The resistance appeared to be suppressed at 35°C and was completely abolished at 40°C. Although heterogeneity in azole resistance among subpopulations of single isolates has been reported for Candida species, the transient changes in expression of resistance under different growth conditions reported here have not been observed in fungal pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This phenomenon was first described in 1999, when researchers observed that a subset of Cryptococcus cells were able to grow at azole concentrations well above the inhibitory concentration in vitro21.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
Chambers, H. F. “. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.781 · Cited by 1,128
Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus
Hartman, B. J., & Tomasz, A. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.1.85 · Cited by 265
Wu, S., de LENCASTRE, H., & Tomasz, A. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.20.6036-6042.1996 · Cited by 241
Sanati, H., Belanger, P. H., Fratti, R. A., & Ghannoum, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2492 · Cited by 221
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis
Spitzer, E. D., Spitzer, S. G., Freundlich, L. F., & Casadevall, A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90354-j · Cited by 165
Susceptibility testing of Cryptococcus neoformans: a microdilution technique
Ghannoum, M. A., Ibrahim, A. S., Fu, Y., Shafiq, M. C., Edwards, J. E., & Criddle, R. S. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.11.2881-2886.1992 · Cited by 145
Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus
Ryffel, C., Strässle, A., Kayser, F. H., & Berger‐Bächi, B. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.724 · Cited by 140
Taxonomic, R. (1980) · Cited by 137
Witt, M. D., Lewis, R. J., Larsen, R. A., Milefchik, E. N., Leal, M. A. E., Haubrich, R., Richie, J., Edwards, J. E., & Ghannoum, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.322 · Cited by 136
Paugam, A., Dupouy‐Camet, J., Blanche, P., Gangneux, J., Tourte-Schaefer, C., & Sicard, D. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.5.975-a · Cited by 117
Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K., & Ghannoum, M. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.169 · Cited by 114
Casadevall, A., Spitzer, E. D., Webb, D., & Rinaldi, M. G. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.6.1383 · Cited by 104
Maki, H., Yamaguchi, T., & Murakami, K. (1994) · Journal of Bacteriology · doi:10.1128/jb.176.16.4993-5000.1994 · Cited by 91
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans
Venkateswarlu, K., Taylor, M., Manning, N. J., Rinaldi, M. G., & Kelly, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.748 · Cited by 75
Nguyen, M. H., & Yu, C. Y. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.471 · Cited by 72
Brandt, M. E., Pfaller, M. A., Hajjeh, R. A., Graviss, E. A., Rees, J., Spitzer, E. D., Pinner, R. W., & Mayer, L. W. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.4.812 · Cited by 72
The Hidden Danger of Primary Fluconazole Prophylaxis for Patients with AIDS
Berg, J., Clancy, C. J., & Nguyen, M. H. (1998) · Clinical Infectious Diseases · doi:10.1086/517056 · Cited by 70
Reversible fluconazole resistance in Candida albicans: a potential in vitro model
Calvet, H. M., Yeaman, M. R., & Filler, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.535 · Cited by 69
Vélez, J. D., Allendoerfer, R., Luther, M., Rinaldi, M. G., & Graybill, J. R. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.2.508 · Cited by 69
Armengou, A., Porcar, C., Mascaró, J. M., & Garcia-Bragado, F. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.6.1337-a · Cited by 68
Sullivan, D. J., Haynes, K., Moran, G. P., Shanley, D. B., & Coleman, D. C. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.7.1739-1744.1996 · Cited by 65
Resistance heterogeneity in methicillin-resistantStaphylococcus aureus
Matthews, P., & Stewart, P. R. (1984) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1984.tb00718.x · Cited by 63
Maki, H., & Murakami, K. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.22.6944-6948.1997 · Cited by 62
de LENCASTRE, H., Figueiredo, A. M. S., & Tomasz, A. (1993) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02389872 · Cited by 54
Impact ofsarandagron methicillin resistance inStaphylococcus aureus
Durán, S. P., Kayser, F. H., & Berger‐Bächi, B. (1996) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1996.tb08394.x · Cited by 52
Azole Drug Resistance as a Cause of Clinical Relapse in AIDS Patients with Cryptococcal Meningitis
Birley, H., Johnson, E. M., McDonald, P., Parry, C. M., Carey, P. B., & Warnock, D. W. (1995) · International Journal of STD & AIDS · doi:10.1177/095646249500600510 · Cited by 51
Methicillin-Resistant Staphylococci: Genetics of the Minority Population
Seligman, S. J. (1966) · Journal of General Microbiology · doi:10.1099/00221287-42-2-315 · Cited by 44
Tribble, D. R., Church, P., & Frame, J. N. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.3.431 · Cited by 44
Fujimura, T., & Murakami, K. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.20.6294-6301.1997 · Cited by 37
Kirkpatrick, W. R., McAtee, R. K., Revankar, S. G., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.5.1330-1332.1998 · Cited by 31
Orni‐Wasserlauf, R., Izkhakov, E., Siegman‐Igra, Y., Bash, E., Polacheck, I., & Giladi, M. (1999) · Clinical Infectious Diseases · doi:10.1086/313546 · Cited by 28
Self-citationSchoofs, A., Odds, F. C., Colebunders, R., Ieven, M., Wouters, L., & Goossens, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1625 · Cited by 26
Varma, A., & Kwon-Chung, K. J. (1994) · Current Genetics · doi:10.1007/bf00326305 · Cited by 19
Self-citation
Cited by
Sorted by citations
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Microbial Cell Individuality and the Underlying Sources of Heterogeneity
Avery, S. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1460 · Cited by 521
Sionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479
Self-citation
Metadata
- Authors
- Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., & Kwon-Chung, K. J.
- Affiliations
- National Institutes of Health (US)
- University of Verona (IT)
- Hadassah Medical Center (IL)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1999-08
- Volume
- 43
- Issue
- 8
- Pages
- 1856-1861
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC89380
- OpenAlex
- W2000804360
- Cited by
- 139
- References
- 36
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 11 · 2021: 5 · 2020: 9 · 2019: 7 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 2 · 2014: 10 · 2013: 7 · 2012: 12
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Cryptococcus neoformans, azole resistance, fluconazole, voriconazole, heteroresistance, clonal subpopulations, cryptococcal meningitis, AIDS, temperature-dependent resistance, loss of resistance, serial isolates
- MeSH terms
- Acquired Immunodeficiency Syndrome, Adult, Amphotericin B, Antifungal Agents, Cryptococcus neoformans, Drug Resistance, Microbial, Humans, Hydrogen-Ion Concentration, Male, Microbial Sensitivity Tests, Osmolar Concentration, Phenotype, Pyrimidines, Staining and Labeling, Temperature, Triazoles, Fluconazole, Meningitis, Fungal, Itraconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review